Hemostatic Changes Following COVID-19 Vaccination

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240812005

Enrollment

500

Registered

2024-08-12

Start date

2021-08-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemostatic changes after COVID-19 vaccination COVID-19 vaccine, D-dimer, Thrombin generation assay, platelet

Interventions

Viral vector COVID-19 vaccine,mRNA COVID-19 vaccine

Experimental Biological/Vaccine,Experimental Biological/Vaccine

ChAdOx1S ,BNT162b2

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Healthy participants aged 18 years or older who received COVID-19 vaccines, including the ChAdOx1-S and BNT162b2 vaccines.

Exclusion criteria

Exclusion criteria: pregnant women, history of arterial or venous thrombotic events, participants treated with anticoagulants/antiplatelet therapy, ongoing cancer treatment, thrombocytopenia, and initial D-dimer elevation

Design outcomes

Primary

Measure	Time frame
Platelet count 21 days median and mean	—

Secondary

Measure	Time frame
D-dimer 21 days Median/mean,endogenous thrombin potential 21 days median,Peak 21 days median/mean,lag time 21 days median,time to peak 21 days median	—

Countries

Thailand

Contacts

Public ContactTarinee Rungjirajittranon

Faculty of Medicine Siriraj Hospita;

taitharee@gmail.com0855551423

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026